Alert detail
LCD L38966: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — Palmetto GBA
What changed
MolDX LDT coverage for inherited cancer syndrome testing in cancer pts
Who’s affected: Oncology billing teams · Effective: April 18, 2024
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 10 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.